Neogen (NEOG) recently reported fourth quarter and full year results, with revenue broadly unchanged year over year and a sharply smaller net loss, and paired this with new revenue guidance for fiscal 2027.

Neogen’s latest earnings update and new fiscal 2027 revenue guidance have come alongside strong share price momentum, with a 30 day share price return of 23.87% and a year to date share price return of 63.86%. Over a longer horizon, the 1 year total shareholder return of 125.79% contrasts with a 3 year total shareholder return that is down 49.02% and a 5 year total shareholder return that is down 72.90%, which shows how recent optimism has followed a much weaker earlier period for investors.

If the earnings story has you rethinking where growth might come from next, it can be useful to see which other healthcare AI related stocks are gaining attention through the 43 healthcare AI stocks.

Bulls interpret Neogen’s shrinking losses and updated guidance as the beginning of a reset. Bears focus on flat revenue and a prolonged period of weak multiyear share performance. Which side does the current valuation appear to support next?

Most Popular Narrative: 12% Undervalued

Neogen’s most followed narrative pegs fair value at $13 per share, which is modestly above the last close of $11.47, and sets out a detailed earnings and margin path behind that view.

Operational improvements and automation at the new Petrifilm production facility, alongside targeted actions to reduce inefficiencies in sample collection and inventory management, are expected to drive gross margin and EBITDA margin improvements over the coming quarters as execution stabilizes and overhead absorption rates improve.

Want to see how Neogen gets from current losses to the earnings needed to back that fair value? The narrative leans heavily on margin repair, a shift in revenue trends, and a richer future earnings multiple. The exact balance between these three pieces is what really drives the $13 figure.

Result: Fair Value of $13 (UNDERVALUED)

However, that fair value narrative still hinges on Neogen resolving integration issues in the 3M Food Safety acquisition, as well as managing ongoing macro and tariff pressure on margins.

Another View on Neogen’s Valuation

The Neogen fair value narrative points to a modest discount at $13 per share, yet the current P/S ratio of 2.9x also sits side by side with a fair ratio estimate of 1.2x. That is a sizeable gap, even though 2.9x is roughly in line with the US Medical Equipment industry and below a 4x peer average. For investors, the question is whether the story leans more toward upside from the narrative or toward valuation risk if sentiment cools.

Next Steps

Given the mixed signals around Neogen’s valuation and recent share price moves, it makes sense to review the underlying data yourself and act promptly. To factor in the key issues raised by other investors, take a close look at the 1 important warning sign.

Looking for more ideas beyond Neogen?

If Neogen's story has you thinking about what else might deserve a spot on your watchlist, this is a good time to widen your research using focused stock lists.

• Target potential mispricings by reviewing companies flagged in the 51 high quality undervalued stocks that pair quality fundamentals with appealing valuations.
• Strengthen your focus on resilience by checking out companies in the 79 resilient stocks with low risk scores that score well on balance sheet and risk metrics.
• Stay ahead of the crowd by scanning the screener containing 19 high quality undiscovered gems that highlight lesser known stocks with solid underlying numbers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.